TEPEZZA

BIOLOGICAL3 trials

Sponsors

Amgen

Conditions

BioavailabilityBioequivalenceChronic (Inactive) Thyroid Eye DiseaseDiffuse Cutaneous Systemic SclerosisThyroid Eye Disease

Phase 1

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

TerminatedNCT04478994

AmgenDiffuse Cutaneous Systemic Sclerosis

Start: 2021-11-17End: 2022-12-08Updated: 2024-06-28

A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

CompletedNCT06563856

AmgenBioavailability, Bioequivalence

Start: 2020-09-22End: 2021-05-27Updated: 2024-08-21

Phase 4

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

CompletedNCT04583735

AmgenChronic (Inactive) Thyroid Eye Disease, Thyroid Eye Disease

Start: 2021-09-02End: 2023-10-12Updated: 2024-07-01

Related Papers

OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients

Journal of the Endocrine Society2023-10-01

SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease

Journal of the Endocrine Society2023-10-01